𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia

✍ Scribed by Li, Juyi; Wang, Xiufang; Zhang, Zhaoqing; Zou, Jili; Chen, Yonggang; Wang, Xiong; Wu, Jinhu

Book ID
124162637
Publisher
Informa plc
Year
2013
Tongue
English
Weight
127 KB
Volume
30
Category
Article
ISSN
0300-7995

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

CYP2D6 polymorphisms and the impact on t
CYP2D6 polymorphisms and the impact on tamoxifen therapy
✍ Jacob N. Beverage; Tristan M. Sissung; Amy M. Sion; Romano Danesi; William D. Fi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 122 KB

The cytochrome P450 2D6 (CYP2D6) is an enzyme known to metabolize a variety of xenobiotics and drugs. Inter-individual variation in the metabolic capacity of this enzyme has been extensively studied and associations with genotype have been established. Genetic polymorphisms have been grouped as nonf

CYP2D6-debrisoquine hydroxylase gene pol
CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy
✍ V. PlantΓ©-Bordeneuve; O. Bandmann; G. Wenning; N. P. Quinn; S. E. Daniel; Prof. πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 200 KB

Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinson's disease (PD) when compared with controls. We have investigated C YP2D6 polymorphism in 91 patients with mult